Evidence map›Paper›PMID 20408311›Full record

ReviewClinical medicine (London, England)2010

Management of acute exacerbations of chronic obstructive pulmonary disease: the first 24 hours.

Michael Greenstone

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical medicine (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Prehospital prognosis is difficult in patients with acute exacerbation of chronic obstructive pulmonary disease.Scandinavian journal of trauma, resuscitation and emergency medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael GreenstoneMedical Chest Unit, Castle Hill Hospital, Cottingham. mike.greenstone@hey.nhs.uk
Castle Hill Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Successful outcome is more likely with early treatment and lesser degrees of acidosis. While aiming for maximum treatment for the first 24 hours, some patients improve so rapidly that they can discontinue after a shorter time. Most patients need a full face mask and oxygen, and nebulised bronchodilators can be incorporated. If radiological consolidation, excessive secretions and/or confusion are present, the chance of failure is increased but is not an absolute contraindication. The presence of a pneumothorax necessitates intercostal drainage. A useful summary statement has recently been published. Patients who are obtunded and peri-arrest require immediate intubation and mechanical ventilation. There is some evidence that intensivists are reluctant to accept COPD exacerbators to the intensive care unit because of the perceived low survival rates or concerns about weaning delays after intubation. In fact, the prognosis may be better than in many other patients with multi-organ failure. Patients can often be quickly weaned on to NIV and returned to the ward after an initial period of invasive support and secretion management. Initial assessment and the past history should identify those markedly disabled patients with recurrent admissions who are likely to be entering the terminal stages of their illness in whom intubation is inappropriate. Here, NIV may be the ceiling of treatment, providing useful symptom palliation while waiting for treatment to

Indexed as

Acute DiseaseBronchodilator AgentsHumansOxygen Inhalation TherapyPulmonary Disease, Chronic ObstructiveRespiration, ArtificialRespiration DisordersTime FactorsBronchodilator Agents

Identifiers

PMID20408311
PMCPMC4954485
OpenAlexW2099488321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.